Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.5 (EPT/RI)Replacement - Astrazeneca PLC

6 May 2014 15:56

RNS Number : 3852G
Morgan Stanley Capital Services LLC
06 May 2014
 



AMENDMENT 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

02 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

YES

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 607,365

 31.0300 USD

 30.6200 USD

 COMMON STOCK

 SALES

 570,435

 31.0500 USD

 30.6300 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 COMMON STOCK

 CFD

 LONG

 80,021

 30.6635 USD

 COMMON STOCK

 CFD

 LONG

 6,300

 30.7098 USD

 COMMON STOCK

 CFD

 LONG

 4,700

 30.7214 USD

 COMMON STOCK

 CFD

 LONG

 300

 30.7233 USD

 COMMON STOCK

 CFD

 LONG

 12

 30.7300 USD

 COMMON STOCK

 CFD

 LONG

 10

 30.7300 USD

 COMMON STOCK

 CFD

 LONG

 9

 30.7300 USD

 COMMON STOCK

 CFD

 LONG

 11

 30.7300 USD

 COMMON STOCK

 CFD

 LONG

 400

 30.7300 USD

 COMMON STOCK

 CFD

 LONG

 35,750

 30.7334 USD

 COMMON STOCK

 CFD

 LONG

 200

 30.7400 USD

 COMMON STOCK

 CFD

 LONG

 4,800

 30.7494 USD

 COMMON STOCK

 CFD

 LONG

 1,900

 30.7500 USD

 COMMON STOCK

 CFD

 LONG

 25,202

 30.7500 USD

 COMMON STOCK

 CFD

 LONG

 1,000

 30.7500 USD

 COMMON STOCK

 CFD

 LONG

 1

 30.8000 USD

 COMMON STOCK

 CFD

 LONG

 1,490

 30.8103 USD

 COMMON STOCK

 CFD

 LONG

 16,389

 30.8104 USD

 COMMON STOCK

 CFD

 LONG

 1,398

 30.8297 USD

 COMMON STOCK

 CFD

 SHORT

 6,598

 30.6417 USD

 COMMON STOCK

 CFD

 SHORT

 1,755

 30.6854 USD

 COMMON STOCK

 CFD

 SHORT

 239

 30.6854 USD

 COMMON STOCK

 CFD

 SHORT

 1,307

 30.6999 USD

 COMMON STOCK

 CFD

 SHORT

 8,788

 30.6999 USD

 COMMON STOCK

 CFD

 SHORT

 1,060

 30.7070 USD

 COMMON STOCK

 CFD

 SHORT

 601

 30.7070 USD

 COMMON STOCK

 CFD

 SHORT

 248

 30.7071 USD

 COMMON STOCK

 CFD

 SHORT

 513

 30.7071 USD

 COMMON STOCK

 CFD

 SHORT

 5,100

 30.7121 USD

 COMMON STOCK

 CFD

 SHORT

 2,000

 30.7300 USD

 COMMON STOCK

 CFD

 SHORT

 162,760

 30.7344 USD

 COMMON STOCK

 CFD

 SHORT

 37

 30.7372 USD

 COMMON STOCK

 CFD

 SHORT

 237

 30.7372 USD

 COMMON STOCK

 CFD

 SHORT

 500

 30.7460 USD

 COMMON STOCK

 CFD

 SHORT

 39,600

 30.7500 USD

 COMMON STOCK

 CFD

 SHORT

 1,900

 30.7500 USD

 COMMON STOCK

 CFD

 SHORT

 18,200

 30.7500 USD

 COMMON STOCK

 CFD

 SHORT

 25,202

 30.7500 USD

 COMMON STOCK

 CFD

 SHORT

 9,500

 30.7513 USD

 COMMON STOCK

 CFD

 SHORT

 64,500

 30.7542 USD

 COMMON STOCK

 CFD

 SHORT

 125,100

 30.8151 USD

 COMMON STOCK

 CFD

 SHORT

 97

 30.8463 USD

 COMMON STOCK

 CFD

 SHORT

 1,063

 30.8472 USD

 COMMON STOCK

 CFD

 SHORT

 17,130

 30.9186 USD

 COMMON STOCK

 CFD

 SHORT

 400

 30.9250 USD

 COMMON STOCK

 CFD

 SHORT

 11,700

 30.9829 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

06 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERLLFESEEIRIIS
Date   Source Headline
1st Mar 20178:51 amRNSPress Release
27th Feb 201710:45 amRNSPress Release
24th Feb 20172:19 pmRNSPress Release
22nd Feb 20177:00 amRNSCancellation of UK Listing
31st Jan 20172:56 pmRNSFourth Quarter and Full-Year 2016 Results
24th Nov 20153:20 pmRNSForm 8.3 - Pfizer Inc
24th Nov 20153:19 pmRNSForm 8.3 - Pfizer, Inc.
24th Nov 201512:14 pmRNSForm 38.5(b) - Pfizer Inc
24th Nov 201511:49 amRNSForm 8.1a - Pfizer Inc
24th Nov 201511:46 amRNSForm 38.5(a) - Pfizer Inc
24th Nov 201510:41 amRNSRule 38.5 - Pfizer INC
24th Nov 20157:00 amRNSForm 38.5(b) - Pfizer Inc
23rd Nov 20156:11 pmRNSForm 38.5(a) - Pfizer Inc
23rd Nov 20155:58 pmRNSForm 8.1a - Pfizer Inc
23rd Nov 20153:40 pmRNSForm 8.3 - PFIZER INC
23rd Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc Amendment
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20153:28 pmRNSForm 8.3 - ALLERGAN PLC
23rd Nov 20153:21 pmRNSForm 8.3 - Pfizer, Inc.
23rd Nov 20152:56 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:39 pmRNSForm 8.3 - Pfizer Inc
23rd Nov 20152:29 pmRNSForm 8.3 - Allergan Plc
23rd Nov 201512:16 pmRNSForm 8.1 - [Pfizer Inc.]
23rd Nov 201512:04 pmRNSForm 38.5a
23rd Nov 201511:57 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 38.5b
23rd Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
23rd Nov 201510:58 amRNSRule 38.5 - Pfizer INC
20th Nov 20153:43 pmRNSForm 8.3 - Pfizer Inc.
20th Nov 20153:34 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:25 pmRNSForm 8.3 - Allergan plc
20th Nov 20153:21 pmRNSForm 8.3 - PFIZER INC
20th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
20th Nov 20153:14 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20153:11 pmRNSForm 8.3 - [PFIZER INC]
20th Nov 20153:07 pmRNSForm 8.3 - Pfizer Inc
20th Nov 20152:58 pmRNSForm 8.3 - Allergan plc
20th Nov 20152:57 pmRNSRule 38.5 - Replacement Pfizer INC
20th Nov 20152:52 pmRNSForm 8.3 - Allergan Plc
20th Nov 20152:44 pmRNSForm 8.3 - Pfizer, Inc.
20th Nov 201512:14 pmRNSForm 8.1 - [Pfizer Inc]
20th Nov 201511:57 amRNSForm 38.5b
20th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
20th Nov 201511:53 amRNSForm 38.5b
20th Nov 201511:53 amRNSForm 38.5(b) - Pfizer Inc
20th Nov 201511:52 amRNSForm 38.5a
20th Nov 201511:18 amRNSForm 38.5(a) - Pfizer Inc
20th Nov 201510:37 amRNSRule 38.5 - Pfizer INC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.